Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

COPD: Pathogenesis and Clinical Features

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The value of myocardial perfusion CZT-SPECT in the assessment of coronary microvascular dysfunction in INOCA patients: a comparative study with caIMR.

The international journal of cardiovascular imaging·2026

Same author

Ailanthone alleviates septic cardiomyopathy by attenuating MYST histone acetyltransferase 1 (MOF)-mediated H4K16 lactylation-driven inflammation.

British journal of pharmacology·2026

Same author

HLA-E single-chain trimer shields gene-edited allogeneic CAR T cells from NK cell attack.

Blood advances·2026

Same author

2'-O-Methylation maintains ribosome structural and translation integrity.

Molecular cell·2026

Same author

Study on the strength and erosion resistance of soil-amended substrates for rock slopes in Fugu County.

Scientific reports·2026

Same author

A systematic assessment of regional landslide risk under typhoon rainfall: a case study of Taishun, Zhejiang, China in September 2016.

Scientific reports·2026

Search research articles

Related Experiment Video

Updated: Sep 10, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Biomarkers in COPD-Associated PH/CCP: Circulating Molecules and Cell-Intrinsic Marker.

Juan Wang¹, Yankun Zhang¹, Huimin Liu¹

¹Department of Respiratory and Critical Care, Tianjin Medical University General Hospital, Tianjin, 300052, People's Republic of China.

International Journal of Chronic Obstructive Pulmonary Disease

|August 21, 2025

Summary

Biomarkers like NT-proBNP and growth factors aid in diagnosing pulmonary hypertension in COPD patients. Forkhead box M1 (FOXM1) shows promise as a future screening tool for this condition.

Keywords:

CCP COPD FOXM1 PH biomarkers chronic cor pulmonale growth factors inflammatory cytokines pulmonary hypertension

More Related Videos

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters

Published on: July 12, 2024

On-Chip Endothelial Inflammatory Phenotyping

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 21, 2012

Related Experiment Videos

Last Updated: Sep 10, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters

Published on: July 12, 2024

On-Chip Endothelial Inflammatory Phenotyping

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 21, 2012

Area of Science:

Pulmonary Medicine
Vascular Biology
Molecular Mechanisms

Background:

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease.
COPD can lead to pulmonary hypertension (PH) and chronic cor pulmonale (CCP), significantly increasing morbidity and mortality.
Vascular remodeling, driven by inflammatory mediators and growth factors under hypoxia, is a key mechanism in COPD-related PH.

Purpose of the Study:

To investigate the molecular mechanisms of vascular remodeling in COPD-related PH.
To evaluate neurohumoral factors (NT-proBNP), inflammatory mediators, growth factors, and FOXM1 as diagnostic markers for COPD with PH and CCP.

Main Methods:

Evaluation of circulating biomarkers including NT-proBNP, inflammatory mediators, and growth factors via blood sampling.
Assessment of intracellular molecular marker FOXM1 through tissue or enriched cell detection.

Main Results:

Circulating biomarkers offer non-invasive, convenient, sensitive, and specific methods for disease screening.
FOXM1 serves as a histopathological marker and a potential target for liquid biopsy.

Conclusions:

Biomarkers like NT-proBNP, inflammatory mediators, and growth factors are valuable for early screening and diagnosis of PH in COPD patients.
FOXM1 presents a promising avenue for future screening strategies, potentially improving patient outcomes and quality of life.